Spots Global Cancer Trial Database for tirelizumab
Every month we try and update this database with for tirelizumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study | NCT06125080 | TNBC - Triple-N... | Utidelone Tirelizumab Bevacizumab | 18 Years - 70 Years | Tongji Hospital | |
| Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | NCT05528367 | Locally Advance... | Nab-PTX,S-1,Tir... Chemoradiation | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study | NCT06125080 | TNBC - Triple-N... | Utidelone Tirelizumab Bevacizumab | 18 Years - 70 Years | Tongji Hospital | |
| Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After Surgery | NCT05844371 | Gastric Cancer | tirelizumab chemotherapy wi... | 30 Years - 90 Years | Yixing People's Hospital | |
| Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC | NCT05189730 | Esophageal Squa... | Tirelizumab Paclitaxel Carboplatin Neoadiuvant rad... | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC | NCT05189730 | Esophageal Squa... | Tirelizumab Paclitaxel Carboplatin Neoadiuvant rad... | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma | NCT05638984 | PFS | Decitabine Inje... tirelizumab | 18 Years - | Fudan University | |
| Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients | NCT05771181 | Colorectal Canc... Microsatellite ... | Vitamin E Fruquintinib Tislelizumab | 18 Years - | Fudan University | |
| Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations | NCT04969029 | Immunotherapy Adjuvant Therap... Colon Cancer MSI-H | Tirelizumab | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients | NCT05771181 | Colorectal Canc... Microsatellite ... | Vitamin E Fruquintinib Tislelizumab | 18 Years - | Fudan University | |
| Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma | NCT06122493 | Esophageal Squa... | Tirelizumab Nab paclitaxel Carboplatin Radiotherapy | 18 Years - 80 Years | Ruijin Hospital | |
| Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC | NCT04819971 | Stomach Cancer | Tirelizumab Trastuzumab Docetaxel S1 Oxaliplatin | 18 Years - | The First Affiliated Hospital of Zhengzhou University | |
| Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma | NCT05092217 | Nasopharyngeal ... | Tirelizumab salvage surgery | 18 Years - 70 Years | Eye & ENT Hospital of Fudan University | |
| Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations | NCT04969029 | Immunotherapy Adjuvant Therap... Colon Cancer MSI-H | Tirelizumab | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | NCT05528367 | Locally Advance... | Nab-PTX,S-1,Tir... Chemoradiation | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations | NCT04969029 | Immunotherapy Adjuvant Therap... Colon Cancer MSI-H | Tirelizumab | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | NCT05528367 | Locally Advance... | Nab-PTX,S-1,Tir... Chemoradiation | 18 Years - 75 Years | Zhejiang Cancer Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
